Parkinson disease

Last updated: April 20, 2026

Parkinson disease

Watch later

Watch later

Anatomy of the abdominal viscera: Blood supply of the foregut, midgut and hindgut
Anal conditions: Clinical
Jaundice: Pathology review
Endocytosis and exocytosis
Osmosis
Nernst equation
Cytoskeleton and intracellular motility
Leukodystrophy
Adrenoleukodystrophy (NORD)
Zellweger spectrum disorders (NORD)
Primary ciliary dyskinesia
Alport syndrome
Ehlers-Danlos syndrome
Osteogenesis imperfecta
Marfan syndrome
Peroxisomal disorders: Pathology review
Vitamin C deficiency
Gel electrophoresis and genetic testing
Polymerase chain reaction (PCR) and reverse-transcriptase PCR (RT-PCR)
ELISA (Enzyme-linked immunosorbent assay)
Karyotyping
DNA cloning
Fluorescence in situ hybridization
Parkinson disease
Blood pressure, blood flow, and resistance
Resistance to blood flow
Compliance of blood vessels
Microcirculation and Starling forces
Changes in pressure-volume loops
Chiari malformation
Syringomyelia
Intracerebral hemorrhage
Epidural hematoma
Neck trauma: Clinical
Nervous system: Brain and spinal cord injuries
Cauda equina syndrome
Lesch-Nyhan syndrome
Anatomical terminology
Breast cancer: Clinical
Prerenal azotemia
Ovarian cysts, cancer, and other adnexal masses: Clinical
Abnormal uterine bleeding: Clinical
Cervical cancer
Prostate cancer
Precocious puberty
Amenorrhea: Pathology review
Estrogen and progesterone
Ovarian sex-cord stromal tumors
Anatomy and physiology of the female reproductive system
Androgen insensitivity syndrome
Ovarian cyst
Benign breast conditions: Pathology review
Postpartum hemorrhage
Parathyroid conditions and calcium imbalance: Clinical
Diabetes mellitus
Hypopituitarism
Opsoclonus myoclonus syndrome (NORD)
Cushing syndrome
Carcinoid syndrome
Toxic multinodular goiter
Vaginal and vulvar disorders: Pathology review
Skin cancer
Erythema multiforme
Vitiligo
Congenital adrenal hyperplasia
Albinism
Sleep apnea
Pneumothorax
Acute respiratory distress syndrome
Laryngomalacia
Sarcoidosis
Obstructive lung diseases: Pathology review
Pulmonary embolism
Emphysema
Retropharyngeal and peritonsillar abscesses
Metachromatic leukodystrophy (NORD)
Mesoderm
Sudden infant death syndrome
Klinefelter syndrome
Hypokalemia: Clinical
Angelman syndrome
Friedreich ataxia
von Hippel-Lindau disease
Non-urothelial bladder cancers
Urinary incontinence
Hypospadias and epispadias
Renal tubular defects: Pathology review
Bladder exstrophy
Rapidly progressive glomerulonephritis
Neurogenic bladder
Hirschsprung disease
Warthin tumor
Jaundice
Seizures: Clinical
Myasthenia gravis
Muscular dystrophy
DNA mutations
Charcot-Marie-Tooth disease
Anatomy clinical correlates: Posterior blood supply to the brain
Vaccinations: Clinical
Rubella virus
Hunger and satiety
Trypanosoma cruzi (Chagas disease)
Gardnerella vaginalis (Bacterial vaginosis)
Spinal cord disorders: Pathology review
Transverse myelitis
Vasculitis: Pathology review
Laryngomalacia
Pneumonia: Pathology review
Superior vena cava syndrome
Deep vein thrombosis and pulmonary embolism: Pathology review
Tuberculosis: Pathology review
Familial hypercholesterolemia

Flashcards

Parkinson disease

0 of 21 complete

Questions

USMLE® Step 1 style questions USMLE

0 of 6 complete

Start
A 70-year-old man with a history of Parkinson disease comes to the office for follow-up. He was diagnosed 6 years ago, and since then, the condition has been well-controlled with levodopa/carbidopa. However, for the past 2 months, the patient reports increased difficulty ambulating, loss of balance and increased rigidity. He is compliant with the treatment and describes fluctuations in the symptoms that improve after he takes the medication. Physical examination reveals diffuse cogwheel rigidity and difficulty walking. A decision is made to add a medication that will descrease the symptoms between levodopa/carbidopa doses. Which of the following best describes the mechanism of action of this medication?  

Transcript

Watch video only

Parkinson disease, named after Doctor James Parkinson, who first described it, is a progressive neurodegenerative condition characterized by the gradual loss of dopamine-producing neurons in a brain region called the substantia nigra.

Long before the time of Doctor Parkinson, signs of this condition appeared in ancient tales. In Homer’s Odyssey, King Nestor, once a fierce and fearless warrior, slowly changed with age. His hands started to tremble, his steps became sluggish, and his body became stiff, so he could no longer join the battle. His story sounds all too familiar to what we today recognize as Parkinson disease.

Now, to understand what was going on with King Nestor, we need to look deep within the brain, specifically at the basal ganglia. The basal ganglia play a major role in carrying out learned motor plans, such as riding a bike to university. Moreover, they help fine-tune and shape movement while also controlling unwanted or unnecessary motor activity. Basal ganglia do this by modulating signals from the motor part of the thalamus to the motor cortex. Once those signals reach the motor cortex, they travel down the spinal cord to activate muscles, so you can spin those wheels and make it to pathology class on time. At the same time, basal ganglia help regulate muscle tone and help maintain posture.

The basal ganglia include the striatum, which consists of the caudate nucleus and putamen; the globus pallidus; the subthalamic nucleus; and the substantia nigra. When it comes to Parkinson disease, the most important player is the substantia nigra. This phrase literally means black substance and originates from its dark appearance, which comes from melanin-rich neurons. You can picture it as a strong shot of espresso tucked into your midbrain, small, dark, and packed with power.

Now, the substantia nigra consists of two parts. The pars reticulata receives signals from the striatum and sends them down to the thalamus, using the inhibitory, calming neurotransmitter GABA. This helps keep your movements steady and prevents unwanted motions from slipping through. On the other hand, the pars compacta contain dopamine-producing neurons that project to the striatum. This connection forms the nigrostriatal pathway, which supplies the striatum with dopamine and helps initiate movement. Without enough dopamine flowing through it, even simple actions, like reaching for your favorite chocolate bar, can become difficult.

In Parkinson disease, the dopamine-producing neurons in the pars compacta slowly die off. As the brain loses more of these neurons over time, it sends weaker signals through the nigrostriatal pathway, which impairs the initiation and control of voluntary movements.

While most of the time, the underlying cause is unknown, we know that several genetic mutations are associated with Parkinson disease. Based on the type of mutation, we can classify Parkinson disease into autosomal dominant and autosomal recessive types.

Autosomal dominant types are associated with mutations in the SCNA gene, which encodes alpha-synuclein that enables neurons to communicate with each other. When the SCNA gene mutates, the cell produces abnormal alpha-synuclein that misfolds and accumulates within neurons, eventually forming Lewy bodies. These round, eosinophilic structures are the hallmark of Parkinson disease. Next, there’s the LRRK2 gene, which encodes leucine-rich repeat kinase 2, an enzyme that's important with intracellular signaling. When this gene mutates, the enzyme stops working, causing various cellular functions to malfunction.

On the flip side, in the autosomal recessive types, we have mutations of the PARK7 gene, which encodes DJ-1 protein; PINK1 gene, which encodes PINK1 protein; and PARK2 gene, which encodes Parkin protein. These proteins are essential for normal mitochondria functioning. When these proteins don’t work as they should, mitochondrial dysfunction sets in, eventually leading to cell damage and death.

It’s also important to remember that some people with Parkinson disease carry mutations in the GBA1 gene. This gene makes an enzyme called glucocerebrosidase, which helps lysosomes break down and clear out cellular waste. When the enzyme doesn’t work properly, cellular waste accumulates, disrupting normal cell processes and eventually causing cell death. These same mutations are known to cause a lysosomal storage disorder called Gaucher disease. However, we are still not sure how this mutation increases the risk of Parkinson disease.

Regardless of the underlying genetic mutation and type, the loss of melanin-rich neurons causes substantia nigra to look much paler than usual. It’s like pouring milk into that cup of espresso tucked in the brain.

As dopamine-producing neurons die off, dopamine levels in the nigrostriatal pathway gradually decline. With less dopamine available, the brain struggles to initiate movement, which results in clinical features we call parkinsonism. Parkinsonism is a clinical syndrome that includes bradykinesia, rigidity, tremor, and postural instability.

Key Takeaways

Parkinson's is a progressive movement disorder caused by degeneration of dopamine-producing neurons in the substantia nigra, specifically in the pars compacta, which leads to resting tremor, rigidity, problems initiating movement, and postural instability, and for which therapy primarily focuses on increasing brain dopamine.

There is no cure for this condition, but medications can increase dopamine levels in the brain and control tremors. There is also deep-brain stimulation, which involves an implantable device that directly sends electrical signals to the basal ganglia that counteract the abnormal signaling in Parkinson's.

Sources

  1. "Robbins & Kumar Basic Pathology. Available from: ClinicalKey Student, (11th Edition). (pg 754-755) " Elsevier Limited (UK) (2022)
  2. "Robbins & Cotran Pathologic Basis of Disease. Available from: ClinicalKey Student, (10th Edition). (pg-1282-1284)" Elsevier Health Sciences (US) (2020.)
  3. "Crush Step 1 E-Book. Available from: ClinicalKey Student, (3rd Edition).(pg-523-524) " Elsevier Limited (UK) (2023)
  4. "Conn's Current Therapy 2025. Available from: ClinicalKey Student, Page 820-826 " Elsevier Limited (UK) (2024 )